Gallagher, E. J., Moore, H., Lacouture, M. E., Dent, S. F., Farooki, A., Goncalves, M. D., Isaacs, C., Johnston, A., Juric, D., Quandt, Z., Spring, L., Berman, B., Decker, M., Hortobagyi, G. N., Kaffenberger, B., Kwong, B. Y., Pluard, T. J., Rao, R. D., Schwartzberg, L. S., & Broder, M. S. (n.d.). expert consensus recommendations for managing hyperglycemia and rash in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) treated with alpelisib (ALP).. Journal of clinical oncology, 40(28), 422. http://access.bl.uk/ark:/81055/vdc_100169172737.0x000037